Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease (NYMC-571)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02675959
Recruitment Status : Recruiting
First Posted : February 5, 2016
Last Update Posted : March 31, 2022
University of California, Los Angeles
Medical College of Wisconsin
Tufts Medical Center
Baylor College of Medicine
Johns Hopkins University
Dana-Farber Cancer Institute
University of Michigan
Children's Hospital Los Angeles
Information provided by (Responsible Party):
Mitchell Cairo, New York Medical College

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024